J. Goldman & Co’s Immunic IMUX Stock Holding History

J. Goldman & Co’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-27,000	Closed	-$853K	–	424
2022 Q3	$853K	Buy	27,000 +16,200	+150%	+$678K	0.04%	265
2022 Q2	$375K	Hold	10,800	–	–	0.02%	298
2022 Q1	$1.22M	Buy	+10,800	New	+$1.25M	0.06%	241

Other funds holding IMUX

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

J. Goldman & Co's IMUX Position: Q4 2022 in Review

J. Goldman & Co sold out of Immunic (IMUX) in Q4 2022, closing a stake of 2,358 shares — an estimated $75K sold.

J. Goldman & Co first reported a position in IMUX in Q1 2022 and held it in 3 quarters. The position peaked at $1.15M in Q1 2022. 58 funds tracked by Wall St. Rank hold IMUX as of Q4 2022.

J. Goldman & Co reported no remaining Immunic position as of Q4 2022 after selling out during the quarter.
J. Goldman & Co sold 2,358 Immunic shares in Q4 2022, an estimated $75K.
J. Goldman & Co first reported a position in Immunic in Q1 2022 and held it in 3 quarters.
J. Goldman & Co's Immunic position peaked at $1.15M in Q1 2022.
58 funds tracked by Wall St. Rank held Immunic as of Q4 2022.

Based on J. Goldman & Co's 13F filing for Q4 2022, filed 14 Feb 2023.